
STOK Stock Forecast & Price Target
STOK Analyst Ratings
Bulls say
Stoke Therapeutics Inc. is advancing its proprietary TANGO approach to restore protein expression, focusing on innovative treatments for diseases such as Dravet syndrome through its lead candidate, zorevunersen. Recent data from Phase I/II studies indicate significant seizure reductions of approximately 82% and cognitive improvements associated with zorevunersen, enhancing the company's risk profile as it prepares for potential Phase 3 trials. The firm's revenue projections for zorevunersen have been adjusted upwards, anticipating a FY28 launch and indicating promising financial upside should the FDA expedite its approval process.
Bears say
Stoke Therapeutics Inc faces potential challenges that contribute to a negative outlook on its stock, primarily stemming from concerns about patent protection and competitive pressures in the Dravet syndrome market. The possibility of a key patent not being issued, extended, or becoming disputed poses significant risks to the company's valuation and market success, which could lead to downward revisions. Additionally, the current treatment landscape for Dravet syndrome is competitive, with multiple therapies achieving substantial market shares, potentially hindering the adoption of Stoke's lead product, zorevunersen, even if it demonstrates long-term benefits.
This aggregate rating is based on analysts' research of Stoke Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
STOK Analyst Forecast & Price Prediction
Start investing in STOK
Order type
Buy in
Order amount
Est. shares
0 shares